Paveway™ PLUS Microbial Expression Platform
Proven, modular workflows for early microbial process development
Paveway™ PLUS offers a flexible suite of modular workflows based on Paveway™, our proven technology platform for efficient microbial expression of proteins, using novel recombinant E. coli strains. This expression system offers industry-leading titers and a track record of more than 130 successfully expressed proteins. Development of a lead strain for recombinant protein expression can be achieved in as little as four weeks through the use of high-throughput, automated procedures.
New enhanced recombinant strain screening workflow
Paveway™ PLUS has recently been enhanced through the development of a new workflow for recombinant strain screening, which includes rapid evaluation of purified product using a scale down/high-throughput robotic approach to protein purification, combined with advanced protein characterization. This enables strain selection based on parallel evaluation of product titer and quality.
Tailored, client-centric solutions to E. coli strain development
Both Paveway™ PLUS workflows enable rapid expression strain screening, lead strain identification, early pre-clinical and clinical material generation, and process scale-up. However, by applying a modular approach to E. coli strain development, initial material generation and analysis, we can provide clients with options for a wide range of scenarios, tailored to each program’s individual needs. This allows flexible strategies to strain selection to be chosen.
INTRODUCING Paveway™ PLUS WORKFLOWS
Core Paveway™ PLUS Workflow
Provides a fast, reliable, and cost-efficient route to lead strain selection with a primary focus on speed, product titer and solubility.
Enhanced Paveway™ PLUS Workflow
Provides a more comprehensive evaluation of purified product, generating additional product quality data to drive decision making and de-risk overall development process. Focus on both titer and product quality for scenarios where a more considered lead strain selection strategy is required.
Multi-candidate assessments of E. coli expressed proteins with similar amino acid sequences can be performed to enable clients to understand expression levels of similar candidates during early stage development. Up to four candidates and two expression routes can be evaluated.
Well proven panel of E. coli host strains selected for their excellent performance characteristics and their ability to express high titers of recombinant proteins at high cell densities in large scale fermentations.
Lead strain generation in as little as four weeks. Platform-based approaches combined with high-throughput robotics supports fast-track process definition and development resulting in shorter timelines to the clinic and market.
High product titers from large scale E. coli microbial fermentations is generally understood to offer the potential of the lowest cost of goods of any biological expression system.
Highly versatile expression system for recombinant proteins using cytoplasmic (soluble or insoluble) and periplasmic expression modalities. An optimal expression strategy can be designed for each individual protein.
Recombinant strains created using the Paveway™ technology show very low levels of plasmid loss in the absence of antibiotic-based selection pressure. This enables us to develop antibiotic-free fermentation processes without loss of product titer.
Process development for microbial fermentation
Analytical development for microbial fermentation and cell culture.
cGMP Microbial Production
A world-leader in microbial fermentation cGMP manufacturing.
Blog: Enabling Faster, Better Decisions in Early Stage Development of Microbial Based Biotherapeutics
An interview with Steve Loftus, PhD, Microbial Business Steering Group Lead